Session Information
-
WCLC 2021
2021 World Conference on Lung Cancer
Presentation Date(s):- September 8 - 14, 2021
- Total Presentations: 1107
All times listed are in Mountain Time MDT (UTC-6:00)
PL - Plenary
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
WS - Workshops
IS - Industry Symposium
MTE - Meet the Expert
BEDG - Brain Exchange Discussion Groups
September 8 Wed
Sep 8 Thursday
September 9 Thu
Sep 9 Friday
September 10 Fri
Sep 10 Saturday
September 11 Sat
Sep 11 Sunday
September 12 Sun
Sep 12 Monday
September 13 Mon
Sep 13 Tuesday
September 14 Tue
Sep 14
-
+
P01 - Early Stage/Localized Disease/Ablative Therapies - Adjuvant Therapy
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Early Stage/Localized Disease/Ablative Therapies
-
+
P01.01 - LIBRETTO-432: A Placebo-Controlled Phase 3 Study of Adjuvant Selpercatinib in Stage IB-IIIA RET Fusion-Positive NSCLC
00:00 - 00:00 | Presenter: Jonathan Goldman
- Abstract
Loading...
-
+
P17 - Immunotherapy (Phase II/III Trials) - First-Line, Advanced, Squamous NSCLC
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
-
+
P17.01 - KEYNOTE-407 China Extension Final Analysis: Pembrolizumab Plus Chemotherapy for the Treatment of Metastatic Squamous NSCLC
00:00 - 00:00 | Presenter: Ying Cheng
- Abstract
Loading...
-
+
PL02 - Plenary 2: Presidential Symposium (Japanese, Mandarin, Spanish Translation Available)
- 06:30 - 08:00
- 9/09/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Plenary
- Track: N.A.
- Moderators:David Harpole, Tetsuya Mitsudomi
-
+
PL02.03 - Lurbinectedin/Doxorubicin versus CAV or Topotecan in Relapsed SCLC Patients: Phase III Randomized ATLANTIS Trial
06:47 - 06:57 | Presenter: Luis Paz-Ares
- Abstract
Loading...
-
+
OA09 - Expanding Immunotherapy Options for Non-Small Cell Lung Cancers
- 09:30 - 10:30
- 9/09/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Oral
- Track: Immunotherapy (Phase II/III Trials)
- Moderators:Rina Hui
-
+
OA09.01 - First-line Nivolumab + Ipilimumab + Chemo in Patients With Advanced NSCLC and Brain Metastases: Results From CheckMate 9LA
09:30 - 09:40 | Presenter: David Carbone
- Abstract
Loading...
-
+
PL02A - Plenary 2: Presidential Symposium (Rebroadcast) (Japanese, Mandarin, Spanish Translation Available)
- 14:30 - 16:00
- 9/09/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Plenary
- Track: N.A.
- Moderators:David Harpole, Tetsuya Mitsudomi
-
+
PL02A.03 - Lurbinectedin/Doxorubicin versus CAV or Topotecan in Relapsed SCLC Patients: Phase III Randomized ATLANTIS Trial
14:47 - 14:57 | Presenter: Luis Paz-Ares
- Abstract
Loading...
-
+
IS14 - Industry Symposium Sponsored by Daiichi Sankyo: Targeting NSCLC: Current and Emerging ADC Therapies
- 16:15 - 17:15
- 9/13/2021
- Location: Industry Symposium Auditorium via Industry Hub
- Not for CME Credit
- Type: Industry Supported Symposium
- Track: N.A.
-
+
IS14.01 - Disease Landscape Overview
16:15 - 16:30 | Presenter: Luis Paz-Ares
- Abstract
No abstract available for this presentation
-
+
MA14 - Pathologic Patterns, Genomic Alterations and Targeted Therapies in NSCLC
- 18:45 - 19:45
- 9/13/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Mini Oral
- Track: Predictive Tumor Based Assays/ Biomarkers/ Pathology
-
+
MA14.02 - RET Fusion Testing in Advanced Non-Small Cell Lung Carcinoma Patients: the RETING Study
18:50 - 18:55 | Presenter: Fernando Lopez-Rios
- Abstract
Loading...
-
+
MA16 - SCLC: New Targets, Biomarkers, and Systemic Therapies
- 20:00 - 21:00
- 9/13/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Mini Oral
- Track: Small Cell Lung Cancer/ NET
-
+
MA16.01 - Subsequent Systemic Therapy After Lurbinectedin Discontinuation in Patients With Small-cell Lung Cancer
20:00 - 20:05 | Presenter: Vivek Subbiah
- Abstract
Loading... -
+
MA16.06 - Durvalumab ± Tremelimumab + Platinum-Etoposide in 1L ES-SCLC: Exploratory Analysis of HLA Genotype and Survival in CASPIAN
20:30 - 20:35 | Presenter: Marina Chiara Garassino
- Abstract
Loading...